Resumen

A large number of patients are switched to second-line antiretroviral therapy, especially in resource limited settings. Lopinavir/Ritonavir is the main drug used in second-line treatment regimens. We describe a patient attending an HIV treatment centre in Kampala, Uganda, who presented with bilateral non-tender pitting inflammatory edema two weeks after switching to a Lopinavir/Ritonavir-containing second-line treatment regimen. The lack of an alternate explanation led us to suspect that Lopinavir/Ritonavir was potentially responsible for the edema.

Palabras clave: Edema Lopinavir/Ritonavir resource-limited setting.

2009-12-14   |   514 visitas   |   Evalua este artículo 0 valoraciones

Vol. 3 Núm.5. Junio 2009 Pags. 405-407. J Infect Developing Countries 2009; 3(5)